GlassScriptPhysician profile
Crystal M Lane
NPI 1437875325
$1,118.00
in general payments reported to CMS, 2019-2025
20 companies · $570 in 2025
The $570 reported for 2025 was more than what 75% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $280 · 2024: $268 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $129.64 | 2023-2025 | |
| Pfizer INC. | $111.93 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $103.43 | 2024-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $81.64 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $80.81 | 2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $67.31 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $65.30 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.75 | 2023 | Spiriva Respimat, Jardiance, Synjardy |
| Insulet Corporation | $29.58 | 2024 | Omnipod |
| Amgen INC. | $27.41 | 2023 | Prolia, Evenity |
| Alk-Abello, INC | $25.27 | 2025 | Neffy, Grastek, Odactra |
| Ars Pharmaceuticals Operations, INC. | $20.43 | 2025 | Neffy |
| Corium, LLC | $20.39 | 2024 | Azstarys |
| Abbvie INC. | $17.68 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.38 | 2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.88 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $13.65 | 2025 | Capvaxive, Gardasil 9, Vaxelis |
| Ibsa Pharma INC. | $13.63 | 2025 | Licart, Flector, Tirosint |
| Novartis Pharmaceuticals Corporation | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.